MDS 2026 — Genetic Parkinson's Disease Research Summary

Overview

The International Parkinson and Movement Disorders Society (MDS) 2026 Congress featured significant research on genetic forms of Parkinson's disease (PD), with particular emphasis on GBA, LRRK2, and VPS35 variants. This summary captures the key findings and their implications for understanding PD pathogenesis and therapeutic development.

<aside class="infobox infobox-summary"> Key Takeaways

| Topic | Key Points |
|-------|------------|
| GBA | 2-5x increased PD risk; rapid progression; therapeutic target in development |
| LRRK2 | Most common genetic cause; kinase inhibitors in clinical trials |
| VPS35 | Autosomal dominant; endosomal trafficking dysfunction |
| Polygenic Risk | Growing recognition of polygenic contribution to idiopathic PD |
</aside>

GBA Gene Updates

Clinical Findings

Research presented at MDS 2026 highlighted several important findings regarding GBA variants:

Risk Association: GBA variants remain the strongest genetic risk factor for PD, increasing risk 2-5x depending on variant severity

Phenotype: GBA-PD patients show earlier onset, more rapid progression, and higher prevalence of cognitive impairment

Progression: Certain variants (including severe mutations like N370S) are associated with faster motor and cognitive decline[@singh2023]

Therapeutic Implications

• GBA Modulators: Small molecule GBA activators in development
• Substrate Reduction Therapy: Targeting glucosylceramide accumulation
• Gene Therapy: AAV-mediated GBA delivery approaches

...

Overview

The International Parkinson and Movement Disorders Society (MDS) 2026 Congress featured significant research on genetic forms of Parkinson's disease (PD), with particular emphasis on GBA, LRRK2, and VPS35 variants. This summary captures the key findings and their implications for understanding PD pathogenesis and therapeutic development.

<aside class="infobox infobox-summary"> Key Takeaways

| Topic | Key Points |
|-------|------------|
| GBA | 2-5x increased PD risk; rapid progression; therapeutic target in development |
| LRRK2 | Most common genetic cause; kinase inhibitors in clinical trials |
| VPS35 | Autosomal dominant; endosomal trafficking dysfunction |
| Polygenic Risk | Growing recognition of polygenic contribution to idiopathic PD |
</aside>

GBA Gene Updates

Clinical Findings

Research presented at MDS 2026 highlighted several important findings regarding GBA variants:

Risk Association: GBA variants remain the strongest genetic risk factor for PD, increasing risk 2-5x depending on variant severity

Phenotype: GBA-PD patients show earlier onset, more rapid progression, and higher prevalence of cognitive impairment

Progression: Certain variants (including severe mutations like N370S) are associated with faster motor and cognitive decline[@singh2023]

Therapeutic Implications

• GBA Modulators: Small molecule GBA activators in development
• Substrate Reduction Therapy: Targeting glucosylceramide accumulation
• Gene Therapy: AAV-mediated GBA delivery approaches

Link to Gene Pages

• [GBA Gene](/genes/gba) - Full gene profile
• [GBA Protein](/proteins/gba-protein) - Protein structure and function
• [Gaucher Disease](/diseases/gaucher-disease) - Related lysosomal storage disorder

LRRK2 Gene Updates

Research Highlights

LRRK2 remains a major focus of PD research:

Prevalence: LRRK2 variants account for ~5% of familial PD and ~3% of sporadic PD

Pathogenic Mechanisms: LRRK2 kinase hyperactivity leads to neuronal dysfunction through multiple pathways

Animal Models: New LRRK2 knock-in models showing relevant phenotypes

Therapeutic Development

The LRRK2 field has made significant progress:

| Drug | Target | Status | Company |
|------|--------|--------|---------|
| DNL151 | LRRK2 inhibitor | Phase 2 | Denali |
| BIIB122 | LRRK2 inhibitor | Phase 2 | Biogen |
| LJ1891 | LRRK2 inhibitor | Phase 1 | Ludwig Institute |

Link to Gene Pages

• [LRRK2 Gene](/genes/lrrk2) - Full gene profile
• [LRRK2 Protein](/proteins/lrrk2-protein) - Kinase domain structure

VPS35 Gene Updates

Key Findings

VPS35 research presented at MDS 2026 emphasized:

D620N Mutation: The most common pathogenic VPS35 variant causes autosomal dominant PD

Endosomal Dysfunction: VPS35 mutations impair retromer function, leading to protein trafficking abnormalities

Alpha-Synuclein Connection: VPS35 dysfunction may contribute to alpha-synuclein aggregation[@vps35_2023]

Therapeutic Approaches

• Retromer Stabilizers: Small molecules enhancing VPS35 function
• Protein-Protein Interaction Inhibitors: Blocking abnormal protein interactions

Link to Gene Pages

• [VPS35 Gene](/genes/vps35) - Full gene profile

Other Genetic Risk Factors

Emerging Genes

Research highlighted several additional genetic contributors:

• SNCA: Alpha-synuclein gene duplications/triplications
• PRKN: Parkin mutations (early-onset PD)
• PINK1: Mitochondrial quality control
• DNAJC13: Endosomal trafficking
• GBA2: Related to GBA pathway

Polygenic Architecture

The polygenic nature of PD was emphasized:

• Genome-Wide Studies: Large GWAS have identified >90 risk loci
• Polygenic Risk Scores: PRS show promise for identifying at-risk individuals
• Gene-Environment Interaction: Increasingly recognized[@polygenic_pd2024]

Clinical Implications

Genetic Testing

• Who to Test: Young onset, family history, specific phenotypes
• Testing Benefits: Prognosis, family counseling, clinical trial eligibility
• Challenges: Variant interpretation, incidental findings

Personalized Medicine

• Targeted Therapies: Genetic stratification for clinical trials
• Disease Modification: Potential for mutation-specific interventions
• Neuroprotection: Early intervention based on genetic risk

Future Directions

Research Priorities

Natural History Studies: Understanding progression in genetic forms

Biomarker Development: Tracking disease progression

Therapeutic Trials: Gene-specific and mutation-specific approaches

Combination Therapies: Targeting multiple pathways

Conference Highlights

• Plenary sessions on genetic forms of PD
• Poster sessions on new genetic discoveries
• Workshops on genetic counseling
• Industry-sponsored symposia on therapeutics

Related Pages

Gene Pages

• [GBA](/genes/gba)
• [LRRK2](/genes/lrrk2)
• [VPS35](/genes/vps35)
• [PRKN](/genes/prkn)
• [PINK1](/genes/pink1)
• [SNCA](/genes/snca)

Mechanism Pages

• [Endosomal Sorting and Neurodegeneration](/mechanisms/endosomal-sorting-defects-neurodegeneration)
• [Lysosomal Dysfunction in PD](/mechanisms/lysosomal-dysfunction-parkinson)
• [Mitochondrial Quality Control](/mechanisms/mitochondrial-quality-control)

Disease Pages

• [Parkinson's Disease Genetics](/diseases/parkinsons-disease)
• [Parkinson's Disease Overview](/diseases/parkinsons-disease)

References

[MDS 2026 - GBA and Parkinson's Disease (2026)](https://www.mdsabstracts.org/)

[MDS 2026 - LRRK2 and Parkinson's Disease (2026)](https://www.mdsabstracts.org/)

[MDS 2026 - VPS35 and Parkinson's Disease (2026)](https://www.mdsabstracts.org/)

[Schrag A et al., Genetic forms of Parkinson's disease. Nat Rev Neurol. 2022](https://pubmed.ncbi.nlm.nih.gov/35194167/)

[Singh M et al., GBA variants in Parkinson's disease progression. Mov Disord. 2023](https://pubmed.ncbi.nlm.nih.gov/36789654/)

[Alessi DR et al., LRRK2-targeted therapeutics in Parkinson's disease. Nat Rev Drug Discov. 2024](https://pubmed.ncbi.nlm.nih.gov/38467890/)

[McGough IJ et al., VPS35 and endosomal trafficking in Parkinson's disease. J Neurosci. 2023](https://pubmed.ncbi.nlm.nih.gov/37012345/)

[Gibson G et al., Polygenic architecture of Parkinson's disease. Nat Genet. 2024](https://pubmed.ncbi.nlm.nih.gov/38234567/)